J.W. Cole Advisors Inc. Purchases 127 Shares of Zoetis Inc. (NYSE:ZTS)

J.W. Cole Advisors Inc. grew its stake in Zoetis Inc. (NYSE:ZTS) by 8.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,650 shares of the company’s stock after acquiring an additional 127 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Zoetis were worth $326,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. River Street Advisors LLC boosted its holdings in Zoetis by 3.4% in the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after acquiring an additional 58 shares in the last quarter. Perigon Wealth Management LLC boosted its holdings in Zoetis by 0.3% in the fourth quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company’s stock worth $4,654,000 after acquiring an additional 59 shares in the last quarter. TFC Financial Management Inc. boosted its holdings in Zoetis by 3.3% in the third quarter. TFC Financial Management Inc. now owns 1,918 shares of the company’s stock worth $334,000 after acquiring an additional 61 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in Zoetis by 5.0% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,281 shares of the company’s stock worth $253,000 after acquiring an additional 61 shares in the last quarter. Finally, Townsend Asset Management Corp NC ADV boosted its holdings in Zoetis by 0.3% in the third quarter. Townsend Asset Management Corp NC ADV now owns 22,585 shares of the company’s stock worth $3,929,000 after acquiring an additional 66 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Up 0.9 %

Zoetis stock opened at $150.89 on Thursday. The stock has a market cap of $69.01 billion, a PE ratio of 29.76, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The stock has a fifty day moving average of $173.11 and a 200 day moving average of $179.58.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The firm had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.15 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.15%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Barclays dropped their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Stifel Nicolaus lowered their price target on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Finally, The Goldman Sachs Group upped their price target on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $218.00.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the sale, the executive vice president now owns 15,723 shares in the company, valued at $2,725,267.59. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 2,209 shares of company stock worth $371,293. 0.12% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.